Drugs / TQ-B3139
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04675060 | Feb 2021 → Mar 2022 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03099330 | Jul 2017 → Dec 2018 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04398940 | Aug 2020 → Jan 2022 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04056572 | Aug 2019 → Oct 2021 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04009317 | Aug 2019 → Oct 2021 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQ-B3139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04398940 ↗ |
| Known as | CT-711 | “First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell” PMID 35940055 ↗ Aug 2022 |
| Action | Inhibit | “TQ-B3139 is a novel ALK tyrosine kinase inhibitor (TKI)” PMID 35940055 ↗ Aug 2022 |
| Modality | Small molecule | “TQ-B3139 is a novel ALK tyrosine kinase inhibitor (TKI)” PMID 35940055 ↗ Aug 2022 |
| Route | Oral | “TQ-B3139 p.o. qd” NCT03099330 ↗ |
| Target | ALK | “inhibitor of ALK/C-Met tyrosine kinase” NCT03099330 ↗ |
| Target | MET | “inhibitor of ALK/C-Met tyrosine kinase” NCT03099330 ↗ |